Clinical Trials Directory

Trials / Completed

CompletedNCT01622101

Thermogenic Properties of Zantrex-3

Acute Effects of Zantrex-3 on Energy Expenditure and Appetite Sensations

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
23 (actual)
Sponsor
University of Copenhagen · Academic / Other
Sex
Male
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

Background: Zantrex-3® is a popular dietary supplement for weight control, which consists of a combination of yerba mate, guarana, caffeine and damiana. The combination has previously been shown to decrease gastric emptying and its weight controlling effects may be related to increased satiety and thermogenesis. Objective: To investigate the effect of Zantrex-3® on energy expenditure, hemodynamic factors and subjective appetite sensations. Design: Twenty-three men (BMI: 23.9±3.2 kg/m2, mean±SD) participated in a randomized, double-blind, placebo-controlled crossover study. The Zantrex-3® compound contained 365 mg xantines (caffeine and caffeine-like stimulants), yerba mate, guarana and damiana. The thermogenic effect was measured for 3 hours post-intake. Blood pressure (BP), heart rate (HR) and appetite ratings were assessed every half hour.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTThermogenic properties of Zantrex-3®The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by \>7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.

Timeline

Start date
2007-05-01
Primary completion
2007-08-01
Completion
2007-08-01
First posted
2012-06-18
Last updated
2012-06-21

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT01622101. Inclusion in this directory is not an endorsement.